Lung cancer trials recruiting in New York

All Lung cancer trials nationally

Cities in New York

Recruiting trials in New York

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany, Rochester
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  NCT06892548 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
  NCT07554339 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07111520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
  NCT07488923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, East Syracuse, Fresh Meadows, Rochester
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, East Syracuse, Westbury
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, Johnson City
• A Long-term Extension Study of PCI-32765 (Ibrutinib)
  NCT01804686 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
  NCT07045103 · Phase: Not specified · Ages: 22 Years and older · Sex: All (male and female) · New York: New York, The Bronx
• A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
  NCT06905197 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
  NCT05873686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
  NCT07462377 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
  NCT07491497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York, Shirley
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
  NCT07659782 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · New York: New York, The Bronx
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
  NCT06792552 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Registry for People With Lung Cancer
  NCT06424327 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
  NCT07365319 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York, The Bronx, White Plains
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · New York: Albany, East Syracuse, Shirley
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · New York: New York
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Syracuse, The Bronx, Westbury
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York, The Bronx
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  NCT07217171 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07680764 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
  NCT07287995 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New Hyde Park
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
  NCT06875310 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Cooperstown, Schenectady, White Plains
• A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
  NCT06057935 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT07227025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: East Syracuse, Mineola, New York, Schenectady
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: East Syracuse
• A Study of Armored CAR T Cells in People With Cancer
  NCT07783477 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
  NCT06706076 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
  NCT07323732 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
  NCT06345729 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  NCT06983743 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · New York: New York
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Brooklyn, Lake Success, Mineola, New York
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study of Hospital-at-Home for People Receiving Tarlatamab
  NCT06957314 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
  NCT07174583 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
  NCT07277413 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of IDP-001 in Advanced or Metastatic Solid Tumors
  NCT07602842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, Lake Success
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York, The Bronx
• A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest
  NCT05354570 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany, Commack, Harrison, Mineola
• A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  NCT07221474 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany
• A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
  NCT07535437 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
  NCT07594522 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
  NCT06667908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Lung Cancer Risk
  NCT07701733 · Phase: Not specified · Ages: 40 Years to 74 Years · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Lung Cancer Screening in People With Unexplained Weight Loss
  NCT06717334 · Phase: Not specified · Ages: 50 Years to 80 Years · Sex: All (male and female) · New York: Commack, East White Plains, New York, The Bronx
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Study of Mental Health Care in People With Cancer
  NCT06037954 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female) · New York: New York
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
  NCT06855771 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Shirley
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
  NCT06914128 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  NCT06623422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, East Syracuse, New York, Syracuse
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
  NCT04077099 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
  NCT05837767 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  NCT03093116 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · New York: New York
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Babylon, Brooklyn, New Hyde Park, New York
• A Study of Sotorasib in People With Non-Small Cell Lung Cancer
  NCT06582771 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
  NCT06741085 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
  NCT07293247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, The Bronx
• A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
  NCT05657873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
  NCT07037758 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · New York: New York
• A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
  NCT07619339 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
  NCT07027514 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
  NCT07428044 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York, Rochester, The Bronx
• A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
  NCT06807632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of ZEN003694 in People With Squamous Cell Lung Cancer
  NCT05607108 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
  NCT07218146 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Stony Brook, The Bronx
• A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
  NCT06179069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo
• A Study of ZW251 in Participants With Advanced Solid Tumors
  NCT07164313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
  NCT05967689 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, Long Island City, Uniondale
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
  NCT07020117 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of a New PET Scanner in People With Cancer
  NCT07690917 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
  NCT07361562 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York
• A Study of a Side Effects and Resource Navigation Program for People With Cancer
  NCT07646847 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre